Aleniglipron: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions not publicly disclosed. As a small molecule oral tablet, room temperature storage is expected.
Protocol Quick-Reference
Chronic weight management in adults with obesity or overweight
Dosing
Amount
5-120 mg (titrated)
Frequency
Once daily
Duration
36 weeks (Phase 2b trial)
Administration
Route
OralTiming
Start at 5 mg daily with 4-week titration to maintenance doses of 45, 90, or 120 mg once daily. No injection required.
Cycle
Duration
Ongoing (long-term use expected)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk assessment
HbA1c
When: Baseline
Why: Baseline glycemic status
CMP
When: 12 weeks
Why: Monitor liver and kidney function during treatment
๐ก Key Considerations
- โInvestigational compound: not approved by any regulatory authority
- โNon-peptide small molecule: not a peptide despite GLP-1 receptor agonist mechanism
- โPhase 3 development planned for mid-2026
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Weight Management (ACCESS Phase 2b) | Start at 5 mg daily with 4-week titration to maintenance doses of 45 mg, 90 mg, or 120 mg once daily. | Once daily oral tablet | 36 weeks (Phase 2b trial) | The 120 mg dose achieved 11.3% placebo-adjusted weight loss at 36 weeks. 86% of 120 mg participants achieved 5% or more weight loss, and 70% achieved 10% or more. |
| Weight Management (ACCESS II Exploratory) | 240 mg once daily (exploratory higher dose). | Once daily oral tablet | 36 weeks (exploratory study) | The exploratory 240 mg dose showed up to 15.3% placebo-adjusted weight loss at 36 weeks. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
No reconstitution required. Aleniglipron is an oral tablet taken once daily.
๐งStorage Requirements
Storage conditions not publicly disclosed. As a small molecule oral tablet, room temperature storage is expected.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Aleniglipron is an investigational oral drug in Phase 2b development. It is not approved by any regulatory authority.
ACCESS Phase 2b Trial Dosing#
The ACCESS study enrolled 230 adults with obesity or overweight plus comorbidities. All started at 5 mg with 4-week titration to maintenance doses.
| Target Dose | Weight Loss at 36 Weeks (Placebo-Adjusted) | Achieved 5% or More | Achieved 10% or More |
|---|---|---|---|
| 45 mg daily | Lower dose | Not reported | Not reported |
| 90 mg daily | Intermediate | Not reported | Not reported |
| 120 mg daily | 11.3% | 86% | 70% |
| 240 mg (ACCESS II) | Up to 15.3% | Not reported | Not reported |
Administration#
Aleniglipron is taken as a once-daily oral tablet. The 4-week titration from 5 mg to maintenance dose minimizes GI adverse events. Discontinuation rates were 7.7-13.3% across dose groups (mean 10.4%).
Dosing Context#
Aleniglipron belongs to the Metabolic category of research peptides. Dosing protocols for Aleniglipron are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Aleniglipron:
Weight Management (ACCESS Phase 2b)#
Dose: Start at 5 mg daily with 4-week titration to maintenance doses of 45 mg, 90 mg, or 120 mg once daily.
Frequency: Once daily oral tablet
Duration: 36 weeks (Phase 2b trial)
The 120 mg dose achieved 11.3% placebo-adjusted weight loss at 36 weeks. 86% of 120 mg participants achieved 5% or more weight loss, and 70% achieved 10% or more.
Weight Management (ACCESS II Exploratory)#
Dose: 240 mg once daily (exploratory higher dose).
Frequency: Once daily oral tablet
Duration: 36 weeks (exploratory study)
The exploratory 240 mg dose showed up to 15.3% placebo-adjusted weight loss at 36 weeks.
Reconstitution and Preparation#
No reconstitution required. Aleniglipron is an oral tablet taken once daily.
Storage Requirements#
Storage conditions not publicly disclosed. As a small molecule oral tablet, room temperature storage is expected.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Aleniglipron
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.